☆ 4.7 Editorial Material

Targeting the MAPK pathway in advanced BRAF wild-type melanoma

ANNALS OF ONCOLOGY (2019)

期刊

ANNALS OF ONCOLOGY

卷 30, 期 4, 页码 503-505

出版社

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdz054

关键词

类别

Oncology

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.7

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Targeting the mercapturic acid pathway for the treatment of melanoma

Sharad S. Singhal, Saumya Srivastava, Tamara Mirzapoiazova, David Horne, Sanjay Awasthi, Ravi Salgia

Summary: Metastatic melanoma treatment is hindered by dysregulation of signaling pathways like MAP and RLIP, causing cell apoptosis and regression. CDE plays a crucial role in promoting melanoma cell proliferation.

CANCER LETTERS (2021)

添加到收藏夹

Article Oncology

Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3

Kun Zhao, Qiong Dai, Junli Wu, Zhang Wei, Yi Duan, Bo Chen

Summary: This study found that morusin can enhance the inhibitory effect of MAPK pathway inhibitors on BRAF mutant melanoma cells by inhibiting the feedback activation of the STAT3/SOX2 pathway. The combination of morusin and MAPK pathway inhibitors shows greater efficacy in inhibiting BRAF-mutant melanoma and drug-resistant melanoma compared to the use of MAPK pathway inhibitors alone.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Dermatology

The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma

Samantha M. Guhan, Michael Shaughnessy, Anpuchchelvi Rajadurai, Michael Taylor, Raj Kumar, Zhenyu Ji, Sarem Rashid, Keith Flaherty, Hensin Tsao

Summary: Targeting transcriptional dependencies through selective inhibition of CDK9 is an effective method for suppressing therapeutically orphaned BRAF/NRAS/NF1 wild-type melanomas.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study

Elena Lastraioli, Federico Alessandro Ruffinatti, Giacomo Bagni, Luca Visentin, Francesco di Costanzo, Luca Munaron, Annarosa Arcangeli

Summary: In melanoma, immune response and proteasome are associated with tumor development, while genes related to cytosolic ribosomes show a downregulated trend, and transcripts coding for mitoribosome proteins show the opposite trend.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Oncology

A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFG and MYBL2

Olga Vera, Ilah Bok, Neel Jasani, Koji Nakamura, Xiaonan Xu, Nicol Mecozzi, Ariana Angarita, Kaizhen Wang, Kenneth Y. Tsai, Florian A. Karreth

Summary: The miR-29 family of microRNAs plays a tumor suppressive role in melanoma by regulating the expression of pri-miR-29b2 similar to c, which in turn promotes melanoma development by targeting transcription factors MAFG and MYBL2.

CANCERS (2021)

添加到收藏夹

Review Immunology

Targeting ferroptosis as a cell death pathway in Melanoma: From molecular mechanisms to skin cancer treatment

Gita Manzari Tavakoli, Mohammad Hossein Mirzapour, Sepideh Razi, Nima Rezaei

Summary: Melanoma, the most aggressive form of skin cancer, has been extensively studied for the development of efficient treatments. Surgical resection, targeted therapies, and immune checkpoint inhibitors are the best approaches for treating early and advanced/metastatic melanoma. Ferroptosis, an iron-dependent cell death pathway, and its inducers have shown potential in overcoming resistance to conventional therapies in advanced/metastatic melanoma. This review discusses the mechanisms of ferroptosis, its environmental triggers, and its implications for the treatment of melanoma.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

添加到收藏夹

Article Oncology

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

H. Gogas, B. Dreno, J. Larkin, L. Demidov, D. Stroyakovskiy, Z. Eroglu, P. Francesco Ferrucci, J. Pigozzo, P. Rutkowski, J. Mackiewicz, I Rooney, A. Voulgari, S. Troutman, B. Pitcher, Y. Guo, Y. Yan, M. Castro, S. Mulla, K. Flaherty, A. Arance

Summary: The combination therapy of MEK inhibitors and immune checkpoint inhibitors did not show improved progression-free survival compared to monotherapy with pembrolizumab in patients with previously untreated BRAF(V600) wild-type advanced melanoma.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Review Oncology

New Approaches to Targeted Therapy in Melanoma

Manuel Felipe Fernandez, Jacob Choi, Jeffrey Sosman

Summary: Immune checkpoint inhibitors and BRAF/MEK inhibitors are the main treatments for melanoma, but resistance to these therapies emphasizes the need for new treatment options. Monoclonal antibodies and small molecules allow targeted therapy by focusing on specific mediators of cancer. Melanoma has several driver mutations, and targeting them could lead to novel therapies.

CANCERS (2023)

添加到收藏夹

Article Oncology

Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells

Kiran Kumar Reddi, Praveen Guruvaiah, Yvonne J. K. Edwards, Romi Gupta

Summary: The study identified new targets and mechanisms driving resistance to MAPK pathway inhibitors in melanoma cells through unbiased RNA-sequencing and ATAC-seq. Changes in chromatin accessibility affected the expression levels of multiple genes, modulating oncogenic pathways and promoting resistance to inhibitors. This research provides potential new targets for treating melanoma patients resistant to MEK or BRAF inhibitors.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Immunology

SPRED1 deletion confers resistance to MAPK inhibition in melanoma

Julien Ablain, Sixue Liu, Gatien Moriceau, Roger S. Lo, Leonard Zon

Summary: The functional evaluation of genetic lesions in cancer can lead to the discovery of novel tumor suppressors and resistance mechanisms to targeted therapies. In this study, SPRED1 was identified as a tumor suppressor and its loss was associated with resistance to BRAF(V600E) inhibition in melanoma. The findings highlight the importance of understanding genetic factors in cancer progression and treatment resistance.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

添加到收藏夹

Article Oncology

The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries

Orsolya Pipek, Laura Vizkeleti, Viktoria Doma, Donat Alpar, Csaba Bödör, Sarolta Karpati, Jozsef Timar

Summary: Malignant melanoma of the skin, primarily on UV-exposed skin, is commonly associated with mutant BRAF, RAS, and KIT oncogenes. The genetic makeup of triple-wild-type melanoma (BRAF, NRAS, and NF1) has been studied before, but with mixed rare and common histopathological subtypes. In this study, whole genome sequencing was used to characterize triple-wild-type melanoma, excluding rare histopathological subtypes. Unrecognized drivers were identified among passenger mutations in some cases.

CANCERS (2023)

添加到收藏夹

Article Surgery

A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients

Stefano Guadagni, Odysseas Zoras, Giammaria Fiorentini, Francesco Masedu, Konstantinos Lasithiotakis, Donatella Sarti, Antonietta Rosella Farina, Andrew Reay Mackay, Marco Clementi

Summary: The study investigated multidisciplinary treatments in 62 BRAF wild-type CM patients with locoregional metastases in the inferior limbs and pelvis. The primary endpoint was tumor response, with a focus on locoregional melphalan chemotherapy.

JOURNAL OF SURGICAL RESEARCH (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer

Shengliang Zhang, Lindsey Carlsen, Liz Hernandez Borrero, Attila A. Seyhan, Xiaobing Tian, Wafik S. El-Deiry

Summary: This article summarizes the current progress in targeting wild-type and mutant p53 for cancer therapy using biotherapeutic and biopharmaceutical methods. Strategies include boosting p53 activity, restoring p53 pathway function, targeting p53 in immunotherapy, and combination therapies.

BIOMOLECULES (2022)

添加到收藏夹

Article Cell Biology

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma

Elisabetta Vergani, Giovanni L. Beretta, Mariachiara Aloisi, Matteo Costantino, Cristina Corno, Simona Frigerio, Stella Tinelli, Matteo Dugo, Felice Maria Accattatis, Agnese Granata, Lorenzo Arnaboldi, Monica Rodolfo, Paola Perego, Laura Gatti

Summary: The study investigated the impact of lipid metabolism on melanoma sensitivity to BRAF inhibitors, revealing that targeting lipid metabolism pathways in resistant cells reduces cell growth, increases drug sensitivity, and induces the expression of enzymes involved in fatty acid and cholesterol metabolism.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

添加到收藏夹

Review Oncology

Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis

Olga S. Cherepakhin, Zsolt B. Argenyi, Ata S. Moshiri

Summary: This article reviews the role of molecular pathways, genomic factors, and the tumor microenvironment in the progression of melanoma from local to distant disease. Further research on these elements is necessary for identifying prognostic factors and potential therapeutic targets.

CANCERS (2022)

添加到收藏夹

Article Oncology

Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling

Paul Dent, Laurence Booth, Andrew Poklepovic, John M. Kirkwood

Summary: Melanoma cells expressing mutant B-RAF V600E are sensitive to treatment with neratinib, especially when combined with HDAC inhibitors. Neratinib affects signaling pathways such as ATM, AMPK, ULK1, and PERK, promoting autophagy and reducing expression of toxic proteins.

PIGMENT CELL & MELANOMA RESEARCH (2022)

添加到收藏夹

Article Oncology

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil Khushalani, Justine Cohen, Elizabeth Buchbinder, Kari Kendra, Pauline Funchain, Karl D. Lewis, Robert M. Conry, Bartosz Chmielowski, Ragini R. Kudchadkar, Douglas B. Johnson, Hongli Li, James Moon, Zeynep Eroglu, Brian Gastman, Magdalena Kovacsovics-Bankowski, Krishna S. Gunturu, Scot W. Ebbinghaus, Sama Ahsan, Nageatte Ibrahim, Elad Sharon, Larissa A. Korde, John M. Kirkwood, Antoni Ribas

Summary: In a randomized phase III trial, adjuvant pembrolizumab was found to significantly improve recurrence-free survival (RFS) but not overall survival (OS) compared to the prior standard-of-care immunotherapies for high-risk resected melanoma patients. The proportion of treatment-related adverse events was lower with pembrolizumab compared to IFN alpha-2b or ipilimumab.

CANCER DISCOVERY (2022)

添加到收藏夹

Article Oncology

Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma

Maryam Pourmaleki, Caitlin J. Jones, Charlotte E. Ariyan, Zheng Zeng, Mono Pirun, Daniel A. Navarrete, Yanyun Li, Mianlei Zhang, Subhiksha Nandakumar, Carl Campos, Saad Nadeem, David S. Klimstra, Claire F. Temple-Oberle, Thomas Brenn, Evan J. Lipson, Kara M. Schenk, Julie E. Stein, Janis M. Taube, Michael G. White, Raymond Traweek, Jennifer A. Wargo, John M. Kirkwood, Billel Gasmi, Stephanie L. Goff, Alex D. Corwin, Elizabeth McDonough, Fiona Ginty, Margaret K. Callahan, Andrea Schietinger, Nicholas D. Socci, Ingo K. Mellinghoff, Travis J. Hollmann

Summary: Our study reveals the importance of intact tumor-cell antigen presentation and the role of exhausted CD8(+) T cells in IL2 therapy for melanoma.

CANCER IMMUNOLOGY RESEARCH (2022)

添加到收藏夹

Article Dermatology

Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System

Martha Matsumoto, Sarah Wack, Martin A. Weinstock, Alan Geller, Hong Wang, Francis X. Solano, John M. Kirkwood, Laura K. Ferris

Summary: Primary care-based melanoma screening is associated with increased detection of thin melanoma, raising concerns about overdiagnosis.

JAMA DERMATOLOGY (2022)

添加到收藏夹

Article Oncology

Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells

Ashwin Somasundaram, Anthony R. Cillo, Caleb Lampenfeld, Creg J. Workman, Sheryl Kunning, Lauren Oliveri, Maria Velez, Sonali Joyce, Michael Calderon, Rebekah Dadey, Dhivyaa Rajasundaram, Daniel P. Normolle, Simon C. Watkins, James G. Herman, John M. Kirkwood, Evan J. Lipson, Robert L. Ferris, Tullia C. Bruno, Dario A. A. Vignali

Summary: The study found that about a third of cancer patients analyzed had robust intracellular expression of LAG3 in their peripheral CD8(+) T cells, but not on the cell surface, due to cleavage by ADAM10. This was associated with poor disease prognosis and decreased CD8(+) T-cell function, which could be partially reversed by anti-LAG3.

CANCER IMMUNOLOGY RESEARCH (2022)

添加到收藏夹

Article Oncology

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas

Summary: In this phase III study, the combination of T-VEC and pembrolizumab did not significantly improve progression-free survival or overall survival in patients with advanced melanoma. These findings indicate that this combination therapy is not effective in this patient population.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Targeted Long-Read Bisulfite Sequencing Identifies Differences in the TERT Promoter Methylation Profiles between TERT Wild-Type and TERT Mutant Cancer Cells

Seungjae Lee, Ti-Cheng Chang, Patrick Schreiner, Yiping Fan, Neeraj Agarwal, Charles Owens, Reinhard Dummer, John M. Kirkwood, Raymond L. Barnhill, Dan Theodorescu, Gang Wu, Armita Bahrami

Summary: The study showed that in wild-type cancer cells, there were significant methylation differences in different regions of the TERT promoter between the two epialleles. Decitabine therapy was able to reduce methylation in the core and proximal regions of the promoter, leading to reactivation of the silent allele.

CANCERS (2022)

添加到收藏夹

Article Oncology

Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma

Lilit Karapetyan, William Gooding, Aofei Li, Xi Yang, Andrew Knight, Hassan M. Abushukair, Danielle Vargas De Stefano, Cindy Sander, Arivarasan Karunamurthy, Monica Panelli, Walter J. Storkus, Ahmad A. Tarhini, John M. Kirkwood

Summary: Despite negative sentinel lymph node status, patients with Stage IIB/IIC melanoma have poor melanoma-specific survival. This study identified a novel 12-gene sentinel lymph node signature risk score that can predict disease recurrence in melanoma patients, regardless of sentinel lymph node status.

CANCERS (2022)

添加到收藏夹

Article Oncology

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review

Islam Eljilany, Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood, Vernon K. Sondak, Antoni Ribas, Kenneth F. Grossmann, Ahmad A. Tarhini

Summary: This study aimed to evaluate the incidence of granulomatous and sarcoid-like lesions (GSLs) in high-risk melanoma patients treated with immune checkpoint inhibitors (ICIs). The results showed a total of 11 GSL cases, with ipi10 being the most commonly reported. The cases were mostly grade III and involved various organs such as lung, mediastinal lymph nodes, skin, subcutaneous tissue, and eye.

CANCERS (2023)

添加到收藏夹

Review Oncology

Immunotherapy in Melanoma: Recent Advances and Future Directions

Andrew Knight, Lilit Karapetyan, John M. Kirkwood

Summary: Immunotherapy has shown promise in reducing the risk of melanoma recurrence and improving survival in patients with unresectable disease. This review explores the history of immunotherapy development, highlights landmark trials, and discusses promising treatments for patients who do not respond to current therapies.

CANCERS (2023)

添加到收藏夹

Correction Biochemistry & Molecular Biology

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (16 OCT, 10.1038/s41591-023-02583-2, 2023 )

John M. Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy, Paolo A. Ascierto, Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V. Long

NATURE MEDICINE (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

John Kirkwood, Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller, Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy, Paolo A. Ascierto, Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman, Georgina V. Long

Summary: Nivolumab is an effective and well-tolerated adjuvant treatment for patients with resected stage IIB/C melanoma.

NATURE MEDICINE (2023)

添加到收藏夹

Article Immunology

Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study

John M. Kirkwood, Lisa A. Kottschade, Robert R. McWilliams, Nikhil Khushalani, Sekwon Jang, Sigrun Hallmeyer, David F. McDermott, Hussein Tawbi, Min Che, Cho-Han Lee, Corey Ritchings, Trong Kim Le, Boas Park, Scott Ramsey

Summary: The OPTIMIzE registry study examined the real-world outcomes of immuno-oncology therapies in patients with advanced melanoma. The results showed that the combination of nivolumab and ipilimumab had a higher disease control rate compared to anti-PD-1 monotherapy, but also had more treatment-related adverse events.

IMMUNOTHERAPY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma

Pattra Chun-on, Angela M. Hinchie, Holly C. Beale, Agustin A. Gil Silva, Elizabeth Rush, Cindy Sander, Carla J. Connelly, Brittani K. N. Seynnaeve, John M. Kirkwood, Olena M. Vaske, Carol W. Greider, Jonathan K. Alder

Summary: TERT promoter mutations alone are insufficient to maintain telomeres in melanoma, but together with TPP1 promoter variants, they synergistically enhance telomere maintenance and immortalization in melanoma.

SCIENCE (2022)

添加到收藏夹

Article Medicine, Research & Experimental

Tim-3 mediates T cell trogocytosis to limit antitumor immunity

Ornella Pagliano, Robert M. Morrison, Joe-Marc Chauvin, Hridesh Banerjee, Diwakar Davar, Quanquan Ding, Tokiyoshi Tanegashima, Wentao Gao, Saranya R. Chakka, Richelle DeBlasio, Ava Lowin, Kevin Kara, Mignane Ka, Bochra Zidi, Rada Amin, Itay Raphael, Shuowen Zhang, Simon C. Watkins, Cindy Sander, John M. Kirkwood, Marcus Bosenberg, Ana C. Anderson, Vijay K. Kuchroo, Lawrence P. Kane, Alan J. Korman, Arvind Rajpal, Sean M. West, Minhua Han, Christine Bee, Xiaodi Deng, Xiao Min Schebye, Pavel Strop, Hassane M. Zarour

Summary: Tim-3 blockade disrupts the trogocytosis of tumor-specific CD8(+) T cells and PD-1(+)Tim-3(+) CD8(+) TILs, leading to decreased tumor burden and prolonged survival in melanoma.

JOURNAL OF CLINICAL INVESTIGATION (2022)

添加到收藏夹

暂无数据

Targeting the MAPK pathway in advanced BRAF wild-type melanoma

期刊

出版社

OXFORD UNIV PRESS

关键词

类别

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

评论

主要评分

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

推荐

导出引文

分享论文